ArticleFrontiers in pharmacology2023

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer.

Zhengda Pei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.